Main Article Content
Diabetes mellitus (DM) represents a group of common metabolic diseases that results in inadequate insulin secretion and diminished sensitivity to insulin. Adenosine mimics insulin's effects on lipid and glucose metabolism and blocks those effects on total hepatic glucose output, which raises the possibility that adenosine induces localised insulin resistance in the liver. The purine metabolism enzyme adenosine deaminase (ADA) breaks down adenosine into inosine and ammonia, which lowers the levels of adenosine.
Aims and objectives:
This was a study of correlation between serum adenosine deaminase level and fasting serum insulin levels in patients with type 2 diabetes mellitus.
Materials and methods:
It is a cross sectional study of 70 patients with newly diagnosed or known type 2 diabetes mellitus from outpatient and inpatient department.
Mildly positive correlation was found between serum ADA with FBG, PPBG and HbA1C with r value of 0.085,0.193 and 0.157 respectively. Serum fasting insulin had a mild correlation with FBG and significant correlation with PPBS (p=0.027) and HbA1C (p = 0.022). Serum adenosine deaminase was positively correlated with QUICKI (r=0.126) and serum fasting insulin was strongly and significantly correlated with QUICKI (p=0.0001). Serum adenosine deaminase level and serum fasting insulin were mildly correlated with each other (r=0.201 and p=0.991).
DM type-2 is an important health problem globally. Diabetes is becoming more common and prevalent at a concerning rate. We discovered that patients with poorly managed type-2 DM had the highest levels of ADA. FBS and PPBS had a favourable correlation with ADA. It was discovered that ADA levels and QUICKI had an inversely proportional association. Even if a positive correlation was discovered, more future studies are required to adequately evaluate the function of ADA in the beginning and development of type-2 DM.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010 Jan;33 Suppl 1(Suppl 1): S62-9. doi: 10.2337/dc10-S062. Erratum in: Diabetes Care. 2010 Apr;33(4): e57. PMID: 20042775; PMCID: PMC2797383.
American Diabetes Association Professional Practice Committee; 1. Improving Care and Promoting Health in Populations: standards of Medical Care in Diabetes—2022. Diabetes Care 1 January 2022; 45 (Supplement_1): S8–S16. https://doi.org/10.2337/dc22-S001
GohelMg, Sirajwala Hb, Kalaria Tr, Kamariya Cp.A Studyof Serum Adenosine Deaminase Levelin Patientswith Type 2 Diabetes Mellitus and its correlation with glycemic control. International Journal of Medical and Applied Sciences2013;2(3):259-67
Fain JN, Wieser P B. Effect of Adenosine Deaminase on cyclic adenosine monophosphate accumulation, lipolysis, and glucose metabolism of fat cells.J. Biol. Chem. 1975, 250:1027-34
Kaur A, Kukreja S, Malhotra N, Neha. Serum Adenosine Deaminase Activity and Its Correlation with Glycated Haemoglobin Levels in Patients of Type 2 Diabetes Mellitus. Journal of Clinical and Diagnostic Research. 2012,6(2): 252-256
Sakowicz - Burkiewicz M, Pawelczyk T. Recent advances in understanding the relationship between adenosine metabolism and the function of T and B lymphocytes in diabetes. Journal of Physiology and Pharmacology 2011;62(5):505-12
Anju Gill, Shhiba Kukreja, Naresh Malhotra, Namrata Chhabra. Correlation of Serum Insulin and the Serum Uric Acid Levels with the Glycated Haemoglobin Levels in Patients of Type 2 Diabetes Mellitus. Journal of Clinical and Diagnostic Research.2013;7(7):1295-1297
Niraula, A., Thapa, S., Kunwar, S. et al. Adenosine deaminase activity in type 2 diabetes mellitus: does it have any role? BMC Endocr Disord 18, 58 (2018).
Chen H, Sullivan G, Yue LQ, Katz A, Quon MJ. QUICKI is a useful index of insulin sensitivity in subjects with hypertension. Am J Physiol Endocrinol Metab 2003;284: E804‑12.
Diabetes Care 2021;44(Suppl.1): S15–S33
Jae-Geun L, Dong Gu K, Jung Re Y, Young Ree K, JinSoek K, GwanPyo K, Dae Ho L. Adenosine deaminase activity in patients with type 2 diabetes mellitus and effect of DPP-4 inhibitor treatment on ADA activity. Diabetes Metab J. 2011; 35:149-58.
Sangeetha K, Dharamveer S. Adenosine deaminase activity in Type 2 diabetes mellitus patients. Indian Medical Gazette. 2011; 3:110-3
Amandeep K, Sahiba K, Naresh M, Neha. Adenosine deaminase activity and its correlation with glycated haemoglobin levels in patients of type 2 diabetes mellitus. JCDR. 2012;6(2):252-6.
Nisha SR, Krishnamurthy N, Raghavendra PBN, Ashakiran S, Sumathi ME, Harish R. Role of adenosine deaminase to predict glycemic status in type 2 diabetes mellitus. J Clin Biomed Sci. 2012;2(3):123-32.
Muthiah B, Adarsh LS, Peddi NK, Menon VB. Adenosine deaminase as marker of insulin resistance. Int J Res Med Sci. 2016 Jul;4(7):2972-9.
Gopalratnam Raman P. Management of postprandial blood glucose in diabetes mellitus. Archives of diabetes & obesity. 2018. doi:10.32474/ADO.2018.01.000124
Sitasuwan T, Lertwattanarak R. Prediction of type 2 diabetes mellitus using fasting plasma glucose and HbA1c levels among individuals with impaired fasting plasma glucose: a cross-sectional study in Thailand. BMJ Open. 2020 Nov 10;10(11): e041269. doi: 10.1136/bmjopen-2020-041269. PMID: 33172945; PMCID: PMC7656954.
Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10. doi: 10.1210/jcem.85.7.6661. PMID: 10902785.
Kaur N; Gitanjali 1, Garg R, Tapasvi C, Chawla S, Kaur N. Correlation of Surrogate Markers of Insulin Resistance with Fasting Insulin in Type 2 Diabetes Mellitus Patients: A Study of Malwa Population in Punjab, India. J Lab Physicians. 2021 Sep;13(3):238-244. doi: 10.1055/s-0041-1730884. Epub 2021 Jul 6. PMID: 34602788; PMCID: PMC8481014.
van der Weyden MB, Kelley WN. Human adenosine deaminase. Distribution and properties. The Journal of Biological Chemistry. 1976;251(18):5448–5456.
Vergauwen L, Hespel P, Richter EA. Adenosine receptors mediate synergistic stimulation of glucose uptake and transportby insulin and by contractions in rat skeletal muscle. The Journal of Clinical Invest igation. 1994;93(3):974–981.
Khemka VK, Bagchi D, Ghosh A, et al. Raised Serum Adenosine Deaminase Level in Nonobese Type 2 Diabetes Mellitus. ScientificWorldJournal. 2013; 2013: 404320.
Mills’ S. E. Regulation of porcine adipocyte metabolism by insulin and adenosine. Journal of Animal Science. 1999;77(12):3201–3207
Vannucci S. J., Nishimura H., Satoh S., Cushman S. W., Holman G. D., Simpson I. A. Cell surface accessibility of GLUT4 glucose transporters in insulin-stimulated rat adipose cells. Modulation by isoprenaline and adenosine. Biochemical Journal. 1992;288(1):325–330.
Johansson SM, Lindgren E, Yang J-N, Herling AW, Fredholm BB. Adenosine A1 receptors regulate lipolysis and lipogenesis in mouse adipose tissue—interactions with insulin. European Journal of Pharmacology. 2008;597(1–3):92–101.
Takasuga S, Katada T, Ui M., Hazeki O. Enhancement by adenosine of insulininduced activation of phosphoinositide 3-kinase and protein kinase B in rat adipocytes. The Journal of Biological Chemistry. 1999;274(28):19545–19550
Lee JG, Kang DG, Yu JR, et al. Changes in adenosine deaminase activity in patients with type 2 diabetes mellitus and effect of DPP-4 inhibitor treatment on ADA activity. Diabetes and Metabolism Journal. 2011;35(2):149–158
Pickup J. C., Crook M. A. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41 (10):1241–1248
Morohoshi M., Fujisawa K., Uchimura I., Numano F. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes. 1996;45(3):954–959
Cordero OJ, Salgado FJ, Fernández-Alonso CM, et al. Cytokines regulate membrane adenosine deaminase on human activated lymphocytes. Journal of Leukocyte Biology. 2001;70(6):920–930.
Rutkiewicz J, Gorski J. On the role of insulin of regulation of adenosine deaminase activity in rat tissues. FEBS Letters. 1990;271(1-2):79–80.